Eli Lilly and Company (NYSE:LLY) Trading 0.2% Higher

Eli Lilly and Company (NYSE:LLY) shares were up 0.2% on Monday . The stock traded as high as $736.38 and last traded at $727.59. Approximately 615,776 shares traded hands during mid-day trading, a decline of 80% from the average daily volume of 3,040,383 shares. The stock had previously closed at $726.31.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on LLY. Cantor Fitzgerald reissued an “overweight” rating and set a $815.00 price objective on shares of Eli Lilly and Company in a research report on Monday, April 15th. Citigroup upped their price target on Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a research report on Tuesday, April 2nd. JPMorgan Chase & Co. lifted their price objective on Eli Lilly and Company from $775.00 to $850.00 and gave the company an “overweight” rating in a research report on Friday, March 15th. Wells Fargo & Company increased their target price on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a report on Tuesday, February 6th. Finally, TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $728.05.

Eli Lilly and Company Stock Up 2.0 %

The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94. The firm has a market capitalization of $708.46 billion, a PE ratio of 128.56, a PEG ratio of 1.59 and a beta of 0.34. The company has a fifty day moving average price of $763.89 and a 200-day moving average price of $664.05.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The company had revenue of $9.35 billion for the quarter, compared to the consensus estimate of $8.95 billion. During the same quarter in the prior year, the firm earned $2.09 earnings per share. Eli Lilly and Company’s revenue was up 28.1% on a year-over-year basis. As a group, analysts expect that Eli Lilly and Company will post 12.52 earnings per share for the current year.

Insider Activity

In related news, major shareholder Lilly Endowment Inc sold 54,032 shares of Eli Lilly and Company stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $645.07, for a total value of $34,854,422.24. Following the completion of the transaction, the insider now owns 99,488,598 shares in the company, valued at $64,177,109,911.86. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 0.13% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Versant Capital Management Inc raised its position in Eli Lilly and Company by 1.8% in the 1st quarter. Versant Capital Management Inc now owns 736 shares of the company’s stock worth $573,000 after purchasing an additional 13 shares during the period. Twin Peaks Wealth Advisors LLC raised its holdings in shares of Eli Lilly and Company by 2.0% in the first quarter. Twin Peaks Wealth Advisors LLC now owns 718 shares of the company’s stock worth $559,000 after buying an additional 14 shares during the period. Moseley Investment Management Inc. lifted its stake in shares of Eli Lilly and Company by 0.4% during the 1st quarter. Moseley Investment Management Inc. now owns 3,890 shares of the company’s stock worth $3,027,000 after acquiring an additional 14 shares during the last quarter. CGN Advisors LLC boosted its holdings in Eli Lilly and Company by 1.4% during the 1st quarter. CGN Advisors LLC now owns 1,001 shares of the company’s stock valued at $779,000 after acquiring an additional 14 shares during the period. Finally, Buckhead Capital Management LLC boosted its holdings in Eli Lilly and Company by 0.7% during the 4th quarter. Buckhead Capital Management LLC now owns 2,104 shares of the company’s stock valued at $1,226,000 after acquiring an additional 15 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.